Bone resorption is enhanced by:
**Core Concept**
Bone resorption is a physiological process by which osteoclasts break down and remove bone tissue. This process is crucial for bone remodeling and calcium homeostasis. The enhancement of bone resorption can lead to various bone diseases, including osteoporosis.
**Why the Correct Answer is Right**
The correct answer is Parathyroid hormone-related protein (PTHrP), which is a potent stimulator of osteoclast activity. PTHrP binds to the parathyroid hormone receptor 1 (PTH1R) on osteoblasts, leading to the expression of RANKL (receptor activator of NF-κB ligand) and the subsequent activation of osteoclasts. This results in increased bone resorption. Other factors such as prostaglandins, interleukin-1 (IL-1), and tumor necrosis factor-alpha (TNF-α) can also enhance bone resorption by stimulating osteoclast activity.
**Why Each Wrong Option is Incorrect**
* **Option A:** Prostaglandins are known to enhance bone resorption, but they are not the primary stimulator of osteoclast activity.
* **Option B:** Interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α) can stimulate bone resorption, but they are not as potent as PTHrP in enhancing osteoclast activity.
* **Option C:** Osteoprotegerin (OPG) is a decoy receptor for RANKL, which inhibits osteoclast formation and activation, rather than enhancing bone resorption.
**Clinical Pearl / High-Yield Fact**
Remember that PTHrP is a potent stimulator of osteoclast activity, and its overexpression can lead to increased bone resorption and diseases such as hypercalcemia of malignancy.
**Correct Answer:** C. Osteoprotegerin (OPG) is actually the correct answer for the opposite effect, which is a decoy receptor for RANKL.